Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials

Overview of attention for article published in Schizophrenia Bulletin, February 2025

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 4,290 followers.

@missyTHX1138 May or may not be the same author: William J. Martin, Johnson & Johnson, Inc. https://t.co/LR1PnlrGJR Seneff, et al https://t.co/zjJa4C8CtL

The first paper in this section, https://t.co/9YUSLwq0AW by William P. Horan and colleagues explores: 🔹 Lessons learned from past CIAS clinical trials 🔹 Challenges in large-scale drug development 🔹 New approaches to streamline research while maintainin…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.